Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring

Antoni Bayes-Genis^{1

2

3}, Domingo Pascual-Figal^{3

4

5}

Affiliations

¹ Heart Institute, University Hospital Germans Trias i Pujol, Crta. Canyet s/n, 08916 Badalona, Spain.
² Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
³ CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.
⁴ Cardiology Department, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Murcia, Spain.
⁵ Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Editorial

Antoni Bayes-Genis et al. Eur Heart J. 2023.

. 2023 Aug 14;44(31):2963-2965.

doi: 10.1093/eurheartj/ehad356.

Antoni Bayes-Genis^{1

2

3}, Domingo Pascual-Figal^{3

4

5}

¹ Heart Institute, University Hospital Germans Trias i Pujol, Crta. Canyet s/n, 08916 Badalona, Spain.
² Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
³ CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.
⁴ Cardiology Department, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Murcia, Spain.
⁵ Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

No abstract available

Comment on

NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.
Adamo M, Pagnesi M, Mebazaa A, Davison B, Edwards C, Tomasoni D, Arrigo M, Barros M, Biegus J, Celutkiene J, Čerlinskaitė-Bajorė K, Chioncel O, Cohen-Solal A, Damasceno A, Diaz R, Filippatos G, Gayat E, Kimmoun A, Lam CSP, Novosadova M, Pang PS, Ponikowski P, Saidu H, Sliwa K, Takagi K, Ter Maaten JM, Voors A, Cotter G, Metra M. Adamo M, et al. Eur Heart J. 2023 Aug 14;44(31):2947-2962. doi: 10.1093/eurheartj/ehad335. Eur Heart J. 2023. PMID: 37217188 Clinical Trial.